US FDA approves burosumab for the treatment of tumour-induced osteomalacia (TIO)

Burosumab, a human monoclonal antibody that blocks FGF23, has been approved for the treatment of FGF23-related hypophosphataemia in TIO associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in adults and paediatric patients ≥2 years.

SPS commentary:

Burosumab is currently licensed in the UK for the treatment of X-linked hypophosphataemia with radiographic evidence of bone disease in children 1 year of age and older and adolescents with growing skeletons.


US Food and Drug Administration